Institute for Prevention and Occupational Medicine of the German Social Accident Insurance, Institute of the Ruhr-University Bochum (IPA), Bürkle-de-la-Camp-Platz 1, 44789 Bochum, Germany.
Facility for Synthetic Chemistry, Max Planck Institute for Biophysical Chemistry (MPI BPC), Am Fassberg 11, 37077 Göttingen, Germany.
Chem Res Toxicol. 2021 Nov 15;34(11):2392-2403. doi: 10.1021/acs.chemrestox.1c00301. Epub 2021 Nov 4.
Nonylphenol (NP) is an endocrine-disrupting anthropogenic chemical that is ubiquitous in the environment. Human biomonitoring data and knowledge on internal NP exposure are still sparse, and its human metabolism is largely unknown. Therefore, in this study, we investigated human metabolism and urinary excretion of NP. Three male volunteers received a single oral dose of 1 mg C-labeled NP (10.6-11.7 μg/kg body weight). Consecutive full urine voids were collected for 48 h. A metabolite screening identified nine ring- and/or side chain-oxidized metabolites. We chose the most promising hits, the alkyl chain-oxidized metabolites hydroxy-NP (OH-NP) and oxo-NP, for quantitative investigation next to the parent NP. For this purpose, we newly synthesized specific - 1-oxidized monoisomeric analytical standards. Quantification of the polyisomeric metabolites was performed via online-solid phase extraction-LC-MS/MS with stable isotope dilution using a previously published consensus method. Alkyl chain hydroxylation (OH-NP) constituted the major metabolism pathway representing 43.7 or 62.2% (depending on the mass transition used for quantification) of the NP dose excreted in urine. The urinary excretion fraction () for oxo-NP was 6.0 or 9.3%. The parent NP, quantified via an analogous isomeric C-NP standard, represented 6.6%. All target analytes were excreted predominately as glucuronic acid conjugates. Excretion was rather quick, with concentration maxima in urine 2.3-3.4 h after dosing and biphasic elimination kinetics (elimination half-times first phase: 1.0-1.5 h and second phase: 5.2-6.8 h). Due to its high and insusceptibility to external contamination (contrary to parent NP), OH-NP represents a robust and sensitive novel exposure biomarker for NP. The novel s enable to robustly back-calculate the overall NP intakes from urinary metabolite levels in population samples for a well-informed cumulative exposure and risk assessment.
壬基酚(NP)是一种环境中普遍存在的人为内分泌干扰化学物质。人体生物监测数据和内部 NP 暴露知识仍然稀缺,其人体代谢也知之甚少。因此,在这项研究中,我们研究了 NP 的人体代谢和尿液排泄。三名男性志愿者口服 1 毫克 C 标记的 NP(10.6-11.7μg/kg 体重)。连续收集 48 小时的全尿。代谢产物筛查鉴定出 9 种环和/或侧链氧化代谢产物。我们选择了最有前途的代谢物,烷基链氧化代谢物羟基-NP(OH-NP)和氧代-NP,除了母体 NP 外,还对其进行了定量研究。为此,我们新合成了特定的 1-氧化单异构体分析标准品。通过先前发表的共识方法,使用稳定同位素稀释,通过在线固相萃取-LC-MS/MS 对多异构体代谢物进行定量。烷基链羟化(OH-NP)是主要的代谢途径,占尿液中 NP 剂量排泄的 43.7%或 62.2%(取决于用于定量的质量跃迁)。氧代-NP 的尿排泄分数()为 6.0%或 9.3%。母体 NP 通过类似的 C-NP 标准品进行定量,占 6.6%。所有目标分析物主要以葡萄糖醛酸缀合物形式排泄。排泄相当快,给药后 2.3-3.4 小时尿液中浓度达到峰值,呈双相消除动力学(第一相消除半衰期:1.0-1.5 小时,第二相:5.2-6.8 小时)。由于其高 和不易受到外部污染(与母体 NP 相反),OH-NP 代表一种稳健且敏感的新型 NP 暴露生物标志物。新型 s 能够从人群样本中的尿液代谢物水平可靠地反算总体 NP 摄入量,以便对累积暴露和风险进行明智评估。